Trial Profile
A Multicenter, Open Label, Phase II Study of Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe Study).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms Fol-BRITe
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 26 Jun 2019 Results assessing efficacy of first line treatment with bendamustine and rituximab followed by 90-yttrium (Y) ibritumomab tiuxetan for follicular lymphoma published in the Clinical Cancer Research
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology